Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-04-24 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
总经理工作细则
Governance Information Classification · 95% confidence The document is titled as the "General Manager Work Rules" of a company, detailing the duties, responsibilities, appointment, and governance structure related to the General Manager and senior management. It is a governance-related internal regulation document, not a financial report, announcement, or meeting material. There are no financial statements, earnings data, voting results, or regulatory filings. The content focuses on governance practices and management roles, which fits the definition of Governance Information (CGR). The document length is about 4991 characters, which is sufficient for a detailed governance report rather than a brief announcement.
2025-04-24 Chinese
董事会秘书工作细则
Governance Information Classification · 95% confidence The document is titled as '海思科医药集团股份有限公司 董事会秘书工作细则', which translates to 'Hisun Pharmaceutical Group Co., Ltd. Board Secretary Work Rules'. It details the duties, qualifications, appointment, and legal responsibilities of the company's board secretary. There is no financial data, no mention of financial results, no regulatory filings or announcements about voting, dividends, or capital changes. The content is focused on governance and internal management rules related to the board secretary role. Therefore, it fits best under Governance Information (CGR). The document length is 2838 characters, which is relatively short but contains substantive governance content, not just an announcement or summary. Hence, the classification is CGR with high confidence.
2025-04-24 Chinese
关联交易决策制度
Governance Information Classification · 95% confidence The document is titled "关联交易决策制度" which translates to "Related Party Transaction Decision System". It outlines the rules, principles, reporting, approval, and disclosure procedures for related party transactions within the company. It references compliance with Chinese laws and Shenzhen Stock Exchange listing rules. The document is a governance policy or internal regulation document rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit results, or voting results. It is not a presentation or transcript. It is a detailed governance framework document related to internal rules and procedures for related party transactions. Therefore, it fits best under Governance Information (CGR). The document length is 5338 characters, which is substantive and not a mere announcement or certification, so it is not RPA or RNS.
2025-04-24 Chinese
投资者来访接待管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system for investor visits and communications by 海思科医药集团股份有限公司. It outlines principles, procedures, responsibilities, and compliance with securities laws regarding interactions with investors, analysts, media, and other stakeholders. It includes appointment rules, confidentiality commitments, and record-keeping requirements. There is no financial data, earnings information, or report content. It is not an announcement or publication of a report but a governance and procedural document related to investor relations and disclosure practices. Therefore, it fits best under Governance Information (CGR), which covers internal rules and governance practices related to company operations and communications.
2025-04-24 Chinese
防范控股股东及关联方占用上市公司资金管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '防范控股股东及关联方占用上市公司资金管理制度' (Management System for Preventing Controlling Shareholders and Related Parties from Occupying Company Funds). It outlines rules, responsibilities, and procedures related to preventing misuse of company funds by controlling shareholders and related parties. There are no financial statements, no earnings data, no meeting minutes, no voting results, no legal proceedings updates, no capital or financing updates, no merger or acquisition information, and no executive compensation details. The document is a governance-related internal control policy, focusing on corporate governance and compliance with regulatory requirements. It is not an announcement or a brief summary but a substantive governance document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2675 characters, which is relatively short but contains substantive governance content, not just an announcement or certification. Hence, it is not RPA or RNS.
2025-04-24 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of the 2025 first quarter report and other internal matters. It includes voting results and confirms compliance with relevant laws and regulations. The document is short (1149 characters) and does not contain the actual financial statements or detailed financial data of the quarterly report itself, but rather the approval of that report. It also references other announcements published elsewhere. Therefore, this document is not the Interim/Quarterly Report itself but an announcement of a board meeting resolution related to it. This fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement about internal supervisory board decisions and approvals, not the report itself.
2025-04-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.